Normal physiologic and benign foci with F-18 FDG avidity on PET/CT in patients with breast cancer

Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 4, 2010, Pages 282-289

  Park, Soon Ah ^a   Lee, Kwang Man ^a   Choi, UnJong ^a   Kim, Hun Soo ^a   Kim, Hye Won ^a   Song, Jeong Hoon ^a  

^a Wonkwang University School of Medicine   (South Korea)

Author keywords

Benign; Breast; Carcinoma; F 18 fluorodeoxyglucose; FDG; Physiologic

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADENOMA; ADULT; AGED; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; FRACTURE HEALING; HUMAN; HYPERMETABOLISM; LUNG TUMOR; LYMPH NODE HYPERPLASIA; MAJOR CLINICAL STUDY; MASTECTOMY; MENSTRUAL CYCLE; OSTEOARTHRITIS; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RETROSPECTIVE STUDY; THERMOGENESIS; THYROIDITIS; TUMOR LOCALIZATION;

EID: 79952737115     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-010-0055-7     Document Type: Article

References (26)

1. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150-85.
2. Ko DH, Choi JY, Song YM, Lee SJ, Kim YH, Lee KH, et al. The usefulness of 18F-FDG PET as a cancer screening test. Nucl Med Mol Imaging. 2008;42:444-50.
3. Taira N, Ohsumi S, Takabatake D, Hara F, Takashima S, Aogi K, et al. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18Ffluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Jpn J Clin Oncol. 2008;39:16-21.
4. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006;107:2545-51.
5. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med. 2001;42:1334-7.
6. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med. 2005;35:84-99.
7. Cho YS, Choi JY, Lee SJ, Hyun SH, Lee JY, Choi Y, et al. Clinical significance of focal breast lesions incidentally identified by 18F-FDG PET/CT. Nucl Med Mol Imaging. 2008;42:456-63.
8. Wahl RL. Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. J Nucl Med. 1996;37:1038-41.
9. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
10. Goerres GW, Von Schulthess GK, Hany TF. Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR Am J Roentgenol. 2002;179:1337-43.
11. Bar-Shalom R. Muscle uptake of 18-fluorine fluorodeoxyglucose. Semin Nucl Med. 2000;30:306-9.
12. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-14.
13. Kim S, Chung JK, Kim BT, Kim SJ, Jeong JM, Lee DS, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Positron Imaging. 1999;2:273-9.
14. Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in preand postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266-71.
15. Hughes EC. The effect of enzymes upon metabolism, storage, and release of carbohydrates in normal and abnormal endometria. Cancer. 1976;38:487-502.
16. Himms-Hagen J. Thermogenesis in brown adipose tissue as an energy buffer. N Eng J Med. 1984;311:1549-58.
17. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002;29:1393-8.
18. Cohade C, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. J Nucl Med. 2003;44:170-6.
19. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004;31:125-34.
20. Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EAM, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol. 2007;80:508-15.
21. Isasi CR, Blaufox MRM. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-12.
22. Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, et al. SUV varies with time after injection in 18F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med. 2003;44:1044-50.
23. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-80.
24. Jeong YJ, Lim ST, Kim DW, Jeong HJ, Youn HJ, Jung SH, et al. The clinical significance of diffuse thyroid uptake that is incidentally identified by F-18 FDG PET/CT imaging in patients with breast cancer. J Breast Cancer. 2009;12:309-15.
25. Liu Y. Clinical significance of thyroid uptake on F18-fluorodeoxyglucose positron emission tomography. Ann Nucl Med. 2009;23:17-23.
26. Boiselle PM, Patz Jr EF, Vining DJ, Weissleder R, Shepard JA, McLoud TC. Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Radiographics. 1998;18:1061-9.